NYC startup
fromMedCity News
1 month agoBioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute - MedCity News
BioNTech acquires CureVac to strengthen mRNA capabilities and mitigate legal risks amidst ongoing patent disputes.